GlassScriptPhysician profile
David B Newsome
NPI 1932634813
$3,787.50
in general payments reported to CMS, 2019-2025
31 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $211 · 2021: $733 · 2022: $647 · 2023: $713 · 2024: $778 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $820.17 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $553.22 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $241.59 | 2021-2025 | Veozah |
| Pfizer INC. | $215.95 | 2022-2025 | |
| Novo Nordisk INC | $205.46 | 2020-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $202.30 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $200.25 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.40 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $134.38 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Sumitomo Pharma America, INC. | $132.37 | 2023-2024 | Gemtesa |
| Amgen INC. | $124.64 | 2021-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $91.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.35 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $78.67 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $72.30 | 2022-2024 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $49.48 | 2023-2025 | Keveyis |
| Teva Pharmaceuticals USA, INC. | $48.27 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $47.18 | 2021 | |
| Alexion Pharmaceuticals, INC. | $47.12 | 2023-2024 | Strensiq |
| Biohaven Pharmaceutical Holding Company LTD. | $44.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.98 | 2022-2023 | Eliquis |
| Allergan, INC. | $36.31 | 2020 | |
| Dexcom, INC. | $25.64 | 2025 | Dexcom G6 Transmitter |
| C. R. Bard, INC. & Subsidiaries | $23.12 | 2023 | Bard Urinary Drainage Bag |
| Amarin Pharma, INC. | $21.62 | 2020 | |
| Abbott Laboratories | $16.56 | 2024 | Freestyle Libre |
| Sanofi Pasteur INC. | $16.12 | 2019 | |
| Tactile Systems Technology INC | $15.88 | 2021 | |
| Acella Pharmaceuticals, LLC | $14.91 | 2025 | NP Thyroid 60 |
| Eisai INC. | $13.87 | 2021 | |
| Valeritas, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Newsome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.